Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump administration’s first attempt at kickstarting a rebate pilot.
HRSA discloses manufacturers approved for revised 340B rebate pilot